Stockreport

ORIC Pharmaceuticals (ORIC) Is Down 36.1% After Advancing Lower-Toxicity Prostate Cancer Drug to Phase 3 [Yahoo! Finance]

Oric Pharmaceuticals, Inc.  (ORIC) 
PDF metastatic castration-resistant prostate cancer achieved strong early radiographic progression-free survival with mostly mild side effects, and selected this dose for th [Read more]